Demcizumab/dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.[1]
^OncoMed Pharmaceuticals Inc. "OncoMed Pharmaceuticals Completes Enrollment of Phase 2 YOSEMITE Clinical Trial of Demcizumab in Pancreatic Cancer". GlobeNewswire News Room. Retrieved 2016-11-20.
Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab...
anti-cancer therapeutic. In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic....
Pharmaceuticals joined a cancer stem cell therapeutic development agreement with demcizumab and five other biologics from OncoMed's pipeline. That same year, Sutro...
Global Information